of the gastric body, peritoneal implants, and abdominopelvic lymph node enlargement. Biopsy of right inguinal lymph node and stomach biopsy returned positive for metastatic melanoma. The patient is currently being treated with immunotherapy.

Conclusions The cutaneous melanoma dissemination to the gynecological tract is rare. The prognosis depends on the initial state and in advanced stages the prognosis declines, mainly due to the high rate of metastases, which are mostly lymphatic. Our case report demonstrates a diagnosis of ovarian malignant melanoma which simulated primary ovarian cancer. The differential diagnoses are sex cord-stromal tumors and germ cell tumors.

IGCS19-0193

326 CLINICAL OUTCOMES ASSOCIATED WITH EZH2 EXPRESSION IN HIGH-GRADE OVARIAN SEROUS CARCINOMA

1O Saglam*, 2S Vyas, 2B Reid, 2J Permutt, 2T Sellens, 1Moffitt Cancer Center, Pathology, Tampa, USA; 2Moffitt Cancer Center, Epidemiology, Tampa, USA

10.1136/ijgc-2019-IGCS.326

Objectives Enhancer of Zeste homologue 2 (EZH2), a primary methyltransferase, is over-expressed in cisplatin-resistant ovarian cancer cell lines. We used immunohistochemistry to study the association between EZH2 expression and clinical outcomes in women with high-grade serous ovarian carcinoma (HGSOC).

Methods Levels of EZH2 expression were evaluated in a tissue microarray that included 99 HGSOC cases and 14 non-neoplastic fallopian tube controls. EZH2 expression was quantified by digital microscopy and H-score (0 to 300) was calculated by multiplying percentage of positively stained cells with nuclear intensity. Results were correlated with clinicopathologic parameters. Treatment response was considered complete when patients demonstrated a disappearance of all measurable disease or normalization of CA-125 level for 4 weeks.

Results Most cases (N=73) had a complete response to chemotherapy. EZH2 expression was upregulated in neoplastic tissue compared to normal controls (P<0.0001) and, among tumors, was upregulated in cases with suboptimal debulking (P=0.03). EZH2 expression was not associated with stage of disease (P=0.95) or response to chemotherapy (P=0.14). However, out of 4 cases that displayed high-expression (>90th percentile) of EZH2 in all cores, 3 were incomplete responders (P=0.04). Median overall survival (OS) for patients was 46 months and did not vary by average EZH2 expression (P=0.11); however, high-expressing patients had borderline survival benefit in multivariate analysis (p=0.06).

Conclusions EZH2 expression does not appear to be predictive of chemotherapy response or overall survival in HGSOC. Whether outliers with high expression of EZH2 are at increased risk for incomplete response yet have potentially better OS is worth further exploration.

IGCS19-0033

328 FIRST-TO-SECOND PROGRESSION-FREE SURVIVAL RATIO AS A PREDICTOR FOR OVERALL SURVIVAL IN OVARIAN CANCER

L. Salman*, E. Gandelsman, A. Romano, G. Sabah, A. Jakobson-Setton, A. Borovich, E. Yeoshoua, R. Etien. Rabin Medical Center, Gynecologic Oncology Division- Helen Schneider Hospital for Women, Petach-Tikva, Israel

10.1136/ijgc-2019-IGCS.328

Objectives We aimed to evaluate the impact of first-to-second progression free survival (PFS1/PFS2) ratio on overall survival (OS) in patients with ovarian cancer.

Methods A retrospective cohort study of all patients with ovarian carcinoma treated in one university-affiliated medical